Navigation Links
Karolinska Development and Uminova Invest Sign Co-operation Agreement
Date:1/14/2010

STOCKHOLM and UMEA, Sweden, January 14 /PRNewswire/ -- Karolinska Development AB and Uminova Invest AB have entered into a co-operation agreement that will enrich the flow of investment opportunities available to Karolinska Development and enable cost effective commercial development for Uminova Invest's portfolio companies. The agreement involves evaluation of potential investments; advise to existing portfolio companies as well as exit issues.

Uminova Invest is a regional private equity capital firm providing capital and competence to prospective growth companies and entrepreneurs with a connection to the Umea University or other educational and research activities in the county of Vasterbotten.

"Umea region excels having created a very strong cluster of life science innovations over the past years and this agreement offers us access to some very exciting commercial opportunities", says Conny Bogentoft, CEO of Karolinska Development.

"Over the past years we have had an ongoing exchange with Karolinska Development, this has now been formalized. This formal co-operation agreement provides further opportunities to create viable companies", says Jan Olsson, CEO of Uminova Invest.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first in class products. http://www.karolinskadevelopment.com

About Uminova Invest

Uminova Invest focuses on prospective growth companies and people with interesting ideas and an entrepreneur spirit at a stage when the addition of capital and competence is vital for the company's growth. The idea, product or service must be unique with a high market potential, and must have a connection to the Umea University or other educational and research activities in the county of Vasterbotten. http://www.uminovainvest.se

    For more information, please contact:

    Conny Bogentoft CEO Karolinska Development
    Tel: +46(0)706-88-61-43, e-mail:
    conny.bogentoft@karolinskadevelopment.com

    Jan Olsson CEO Uminova Invest
    Tel: +46(0)703-44-16-80, email: jan.olsson@uminovainvest.se

SOURCE Karolinska Development AB and Uminova Invest AB


'/>"/>
SOURCE Karolinska Development AB and Uminova Invest AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
2. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
3. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
4. Karolinska Development Closes Fully Subscribed New Share Issue
5. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... the results of its 2016 Annual General Meeting, which was ... China . At the Annual ... of KPMG Huazhen LLP as the independent auditors of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building ... team building events, new program offerings and company expansion. , This is ... to include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 ... Company, has expanded its customisable SureSeq™ NGS panel range with ... - allowing fast and cost-effective study of variants in familial ... copy number variation (CNV) detection on a single small panel ... and hotspot content. This includes all exons for LDLR ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):